A Social Enterprise which is applying for B Corporation status. The first fully automated sample-to-result platform. Launching in late 2023 with a respiratory assay to simultaneously detect flu A, flu B, RSV A, RSV B and Covid-19. Low cost testing with no CapEx as the platform is lent. Rugged and mobile it can be used where and when it is most need at infection hotspots.
